Latest & greatest articles for Prophylactic Oophorectomy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Prophylactic Oophorectomy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Prophylactic Oophorectomy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Prophylactic Oophorectomy

1. Prophylactic oophorectomy for the prevention of ovarian cancer

Prophylactic oophorectomy for the prevention of ovarian cancer Prophylactic oophorectomy for the prevention of ovarian cancer Prophylactic oophorectomy for the prevention of ovarian cancer Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Prophylactic oophorectomy for the prevention of ovarian cancer. Lansdale: HAYES, Inc.. Directory Publication. 2013 Authors (...) ' conclusions Bilateral prophylactic oophorectomy (PO) is a surgical procedure that removes both ovaries and is often accompanied by removal of the fallopian tube, when it is referred to as risk-reducing salpingooophorectomy (RRSO). The purpose of PO is to reduce the risk for ovarian, fallopian tube, and peritoneal cancers, especially in women at high risk due to a family history of breast or ovarian cancer, or the presence of mutations in the breast cancer 1 or 2 (BRCA1/2) gene. Final publication URL

2014 Health Technology Assessment (HTA) Database.

2. Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis

Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention (...) of prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM), compared with no intervention, for the prevention of breast cancer and/or ovarian cancer in women with germline BRCA1 mutation. The authors concluded that PBSO with or without PBM was a cost-effective strategy from the perspective of Norwegian society. The economic side of the analysis was robust and transparent, although the sources of clinical information were less clear. Type of economic

2008 NHS Economic Evaluation Database.

3. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. (PubMed)

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. Data concerning the efficacy of bilateral prophylactic oophorectomy for reducing the risk of gynecologic cancer in women with BRCA1 or BRCA2 mutations are limited. We investigated whether this procedure reduces the risk of cancers of the coelomic epithelium and breast in women who carry such mutations.A total of 551 women with disease-associated germ-line BRCA1 or BRCA2 mutations were identified from registries and studied (...) for the occurrence of ovarian and breast cancer. We determined the incidence of ovarian cancer in 259 women who had undergone bilateral prophylactic oophorectomy and in 292 matched controls who had not undergone the procedure. In a subgroup of 241 women with no history of breast cancer or prophylactic mastectomy, the incidence of breast cancer was determined in 99 women who had undergone bilateral prophylactic oophorectomy and in 142 matched controls. The length of postoperative follow-up for both groups

2002 NEJM

4. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients Grann V R, Panageas K S, Whang W, Antman K H, Neugut A I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. Type of intervention Prophylactic treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of Ashkenazi Jewish women and those from high-risk families who tested

1998 NHS Economic Evaluation Database.